AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,007.00GBp
11:14am EST
Change (% chg)

-2.00p (-0.05%)
Prev Close
4,009.00p
Open
3,983.50p
Day's High
4,070.50p
Day's Low
3,935.00p
Volume
3,253,124
Avg. Vol
2,343,363
52-wk High
4,931.68p
52-wk Low
3,746.00p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for... (more)

Overall

Beta: 0.73
Market Cap(Mil.): £50,509.40
Shares Outstanding(Mil.): 1,264.16
Dividend: 131.00
Yield (%): 4.70

Financials

  AZN.L Industry Sector
P/E (TTM): 25.98 31.23 37.84
EPS (TTM): 1.54 -- --
ROI: 6.54 14.70 14.08
ROE: 14.82 15.24 14.83
Search Stocks

AstraZeneca CEO open for deals that pay from day one

LONDON, Feb 4 After a three-year rebuild, Chief Executive Pascal Soriot reckons AstraZeneca's drug pipeline is now "full", but he's still hungry for acquisitions that pay for themselves straight away.

04 Feb 2016

AstraZeneca warns on profits in 2016 as Crestor patent loss weighs

LONDON AstraZeneca warned on Thursday that revenue and earnings would drop this year due to the arrival of cheap generic rivals to Crestor, its top-selling cholesterol drug, which will offset growth in sales of newer medicines.

04 Feb 2016

UPDATE 3-AstraZeneca warns on profits in 2016 as Crestor patent loss weighs

* Q4 revenue $6.40 billion vs consensus $6.29 billion (Adds details on management incentives, further reaction)

04 Feb 2016

BUZZ-AstraZeneca: bottom of FTSE after tepid 2016 forecast

** AstraZeneca down over 3 pct, top FTSE 100 loser after drugmaker warns of a low to mid single-digit pct decline in 2016 rev, core EPS

04 Feb 2016

AstraZeneca sees fall in 2016 earnings as Crestor loss weighs

LONDON, Feb 4 AstraZeneca expects a low to mid single-digit percentage decline in earnings in 2016 as the arrival of cheap generic copies of cholesterol fighter Crestor offsets growth in sales of new medicines, the British-based drugmaker said on Thursday.

04 Feb 2016

BRIEF-AstraZeneca and Incyte announce lung cancer clinical trial collaboration

* AstraZeneca and Incyte announce new lung cancer clinical trial collaboration

11 Jan 2016

BRIEF-Astrazeneca says ties up with Moderna to co-develop immuno-oncology mRNA

* Co and Moderna Therapeutics announce new collaboration to co-develop and co-commercialise immuno-oncology mRNA Therapeutics

11 Jan 2016

BRIEF-AstraZeneca proposes to appoint PWC as external auditor

* Proposal to appoint PriceWaterhouseCoopers LLP as its external auditor for financial year ending Dec. 31, 2017 Source text for Eikon: Further company coverage:

23 Dec 2015

BRIEF-EU Medicines Agency recommends approval of AstraZeneca's gout drug

* Recommends granting a conditional marketing authorisation for AstraZeneca's lung cancer drug Osimertinib

18 Dec 2015

AstraZeneca buys most of Acerta for $4 billion to add cancer drug

LONDON AstraZeneca is to buy 55 percent of privately held biotech firm Acerta Pharma for $4 billion to give it access to a new kind of blood cancer drug, boosting its long-term growth at the cost of a near-term hit to earnings. | Video

17 Dec 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks